 |
 |
 |
|
May 2, 2012 Russo Partners' David Schull to moderate a panel hosted by AMDeC at the NYBA 2012 Annual Meeting May 11, 2012 HONG KONG, May 11, 2012 - OrbusNeich today announced that data from multiple clinical trials published in the spring issue of Cardiology International demonstrate that the Genous Stent is a safe and efficacious alternative in patients with relative clinical contraindications to the use of DES, as defined by the Guidelines on Myocardial Revascularization 2:34 Rapid Response Success on West Nile Virus Check out our latest blog entry: Spring Financing Round-Up: Alder BioPharmaceuticals, Argos Therapeutics and Sutro Biopharma Raise Venture Capital Funding |
|
We focus exclusively on helping private and public healthcare companies to reach and influence their audiences.
From investors and business partners to regulatory agencies, physicians, payers and the general public. Since our founding as Noonan/Russo more than 24 years ago, we have been on a first-name basis with the people you need to be talking to.
Which means you should be talking to us. |
|
|
 |
 |
|
||
 |
 |
